Merck & Co., Inc. (NYSE:MRK) Shares Sold by Lakeview Capital Partners LLC

Lakeview Capital Partners LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 10.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,840 shares of the company’s stock after selling 2,072 shares during the quarter. Lakeview Capital Partners LLC’s holdings in Merck & Co., Inc. were worth $1,502,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. NumerixS Investment Technologies Inc raised its holdings in Merck & Co., Inc. by 138.7% during the second quarter. NumerixS Investment Technologies Inc now owns 32,468 shares of the company’s stock worth $2,722,000 after purchasing an additional 18,868 shares in the last quarter. Girard Partners LTD. raised its holdings in Merck & Co., Inc. by 2.7% during the second quarter. Girard Partners LTD. now owns 103,298 shares of the company’s stock worth $8,661,000 after purchasing an additional 2,720 shares in the last quarter. Alps Advisors Inc. raised its holdings in Merck & Co., Inc. by 15.9% during the second quarter. Alps Advisors Inc. now owns 38,470 shares of the company’s stock worth $3,226,000 after purchasing an additional 5,273 shares in the last quarter. Lowe Wealth Advisors LLC raised its holdings in Merck & Co., Inc. by 12.0% during the second quarter. Lowe Wealth Advisors LLC now owns 1,396 shares of the company’s stock worth $117,000 after purchasing an additional 150 shares in the last quarter. Finally, Bartlett & Co. LLC raised its holdings in Merck & Co., Inc. by 7.0% during the second quarter. Bartlett & Co. LLC now owns 96,074 shares of the company’s stock worth $8,056,000 after purchasing an additional 6,271 shares in the last quarter. 74.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MRK traded up $0.71 during mid-day trading on Friday, reaching $83.59. 6,053,527 shares of the company’s stock were exchanged, compared to its average volume of 10,105,755. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The stock has a market capitalization of $212.31 billion, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. The business’s fifty day simple moving average is $84.01 and its 200-day simple moving average is $82.77. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.27. The business had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period last year, the firm posted $1.19 earnings per share. Equities research analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

A number of analysts have weighed in on MRK shares. Argus raised their price objective on shares of Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Svb Leerink started coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 price objective on the stock. Mizuho raised their price objective on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. set a $96.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus price target of $95.13.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Strangles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.